Cytokinetics CEO sells 7,500 shares at $65.38

Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of common stock.

Rhea-AI Filing Summary

Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of common stock. He sold 7,500 shares of Cytokinetics common stock at $65.38 per share on April 15, 2026.

After this transaction, Blum directly owns 415,330 shares of Cytokinetics common stock. He also has indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($490K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,500	$65.38	$490K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 415,330 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1); Common Stock — 2,083 shares (Indirect, by Trust 2)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Shares sold: 7,500 shares Sale price per share: $65.38 per share Direct holdings after sale: 415,330 shares +2 more

5 metrics

Shares sold 7,500 shares Open-market sale of common stock on April 15, 2026

Sale price per share $65.38 per share Price for 7,500 Cytokinetics common shares sold

Direct holdings after sale 415,330 shares Common stock directly owned by Robert I. Blum after transaction

Indirect holdings – Bridget Blum Trust 2,083 shares Common stock held by The Bridget Blum 2003 Irrevocable Trust

Indirect holdings – Brittany Blum Trust 2,083 shares Common stock held by The Brittany Blum 2003 Irrevocable Trust

Key Terms

open-market sale, Irrevocable Trust, indirect ownership

3 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Irrevocable Trust financial

"Shares held by The Bridget Blum 2003 Irrevocable Trust."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

indirect ownership financial

""direct_or_indirect": "I","nature_of_ownership": "by Trust 1""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) report for Robert Blum?

Cytokinetics reported that President & CEO Robert I. Blum sold 7,500 shares of common stock. The open-market sale was executed on April 15, 2026, at a price of $65.38 per share, according to the Form 4 filing.

How many Cytokinetics (CYTK) shares does Robert Blum hold after this sale?

After the reported sale, Robert I. Blum directly holds 415,330 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

What was the sale price in Robert Blum’s Cytokinetics (CYTK) Form 4?

Robert I. Blum’s Form 4 shows an open-market sale of Cytokinetics common stock at $65.38 per share. The transaction covered 7,500 shares of common stock on April 15, 2026, as disclosed in the filing.

Are any of Robert Blum’s Cytokinetics (CYTK) shares held indirectly?

Yes. The Form 4 shows 2,083 Cytokinetics shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust, in addition to Blum’s direct holdings.

What type of transaction code appears in Robert Blum’s Cytokinetics (CYTK) Form 4?

The Form 4 lists transaction code “S” for Robert I. Blum’s trade, indicating a sale in an open-market or private transaction. The code applies to the 7,500 shares of Cytokinetics common stock sold at $65.38 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		S		7,500	D	$65.38	415,330	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)